ATHERSYS INC. overview

Thinking about buying stock in XORTX Therapeutics, Tempest Therapeutics, Ginkgo Bioworks Holdings, Athersys, or Textainer Group Holdings? PR Newswire NEW YORK, Oct. 23, 2023 NEW YORK , Oct. 23, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XRTX, TPST, DNA, ATHX, and TGH. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. XRTX:...

Thinking about buying stock in AGNC Investment, Lithium Americas, VinFast Auto, Athersys, or Ginkgo Bioworks Holdings? PR Newswire NEW YORK, Oct. 20, 2023 NEW YORK , Oct. 20, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AGNC, LAC, VFS, ATHX, and DNA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. AGNC:...

Thinking about buying stock in Athersys, Mullen Automotive, Lithium Americas, Connexa Sports Technologies, or Freeline Therapeutics Holdings? PR Newswire NEW YORK, Oct. 18, 2023 NEW YORK , Oct. 18, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATHX, MULN, LAC, CNXA, and FRLN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ATHX:...

Thinking about buying stock in Outset Medical, Tempest Therapeutics, Cassava Sciences, Rivian Automotive, or Athersys? PR Newswire NEW YORK, Oct. 13, 2023 NEW YORK , Oct. 13, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OM, TPST, SAVA, RIVN, and ATHX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. OM:...

Thinking about buying stock in Phio Pharmaceuticals, Barrick Gold, Clearmind Medicine, Athersys Inc, or Wheeler Real Estate Investment Trust? PR Newswire NEW YORK, Oct. 12, 2023 NEW YORK , Oct. 12, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PHIO, GOLD, CMND, ATHX, and WHLR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. PHIO:...

Athersys, Inc. (Nasdaq: ATHX), today announced the pricing of its “reasonable best efforts” public offering of 10,937,500 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.32 per share. The Company further agreed to issue to the investors Series A Warrants to purchase up to an aggregate of 10,937,500 shares of common stock and Series B Warrants to purchase up to an aggregate of 10,937,500 shares of common stock. The Series A and Series B Warrants...

Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and six months ended June 30, 2023 and provided a business update. Second Quarter 2023 and Recent Corporate and Operational Highlights: Nominated healthcare executive and strategy consultant Neema Mayhugh, Ph.D. to the Company’s Board of Directors Surpassed two-thirds patient enrollment in the MASTERS-2...

Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announced today the appointment of Neema Mayhugh, PhD to its Board of Directors. Dr. Mayhugh is an executive with more than 20 years of experience in healthcare consulting, industry, academic and hospital settings. Dr. Mayhugh currently serves as the Founder and Managing Partner of Wave Strategy, a consultancy focused on the rapid commercialization of healthcare...